Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Among authors: mochalova a. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Clinical Trial.
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
Neal J, Pavlakis N, Kim SW, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin YC, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T. Neal J, et al. Among authors: mochalova a. J Clin Oncol. 2024 Mar 29:JCO2302166. doi: 10.1200/JCO.23.02166. Online ahead of print. J Clin Oncol. 2024. PMID: 38552197
A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer.
Tsimafeyeu I, Statsenko G, Vladimirova L, Besova N, Artamonova E, Raskin G, Rykov I, Mochalova A, Utyashev I, Gorbacheva S, Kazey V, Gavrilova E, Dragun N, Moiseyenko V, Tjulandin S. Tsimafeyeu I, et al. Among authors: mochalova a. Invest New Drugs. 2023 Apr;41(2):324-332. doi: 10.1007/s10637-023-01340-z. Epub 2023 Mar 13. Invest New Drugs. 2023. PMID: 36907947 Clinical Trial.
Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.
Gershtein ES, Mochalova AS, Korotkova EA, Samoilova EV, Vashketova OI, Kuz'min YB, Sokolov NY, Kushlinskii NE. Gershtein ES, et al. Among authors: mochalova as. Bull Exp Biol Med. 2023 Aug;175(4):481-486. doi: 10.1007/s10517-023-05891-2. Epub 2023 Sep 29. Bull Exp Biol Med. 2023. PMID: 37773572
Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.
Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T, Arduino R, Fomina D, Bogdanov R, Stepanenko T, Ruiz-Seco P, Gónzalez-García A, Chen Y, Li Y, Whelan S, Noviello S; CAN-COVID Investigators. Caricchio R, et al. JAMA. 2021 Jul 20;326(3):230-239. doi: 10.1001/jama.2021.9508. JAMA. 2021. PMID: 34283183 Free PMC article. Clinical Trial.
Soluble forms of PD-1/PD-L immune checkpoint receptor and ligand in blood serum of breast cancer patients: association with clinical pathologic factors and molecular type of the tumor.
Gershtein ES, Korotkova EA, Vorotnikov IK, Sokolov NY, Ermilova VD, Mochalova AS, Kushlinskii NE. Gershtein ES, et al. Among authors: mochalova as. Klin Lab Diagn. 2022 Feb 23;67(2):76-80. doi: 10.51620/0869-2084-2022-67-2-76-80. Klin Lab Diagn. 2022. PMID: 35192751 English.
[Magnetotherapy in patients with malignant tumors receiving immunotherapy].
Koneva ES, Mochalova AS, Suetina MS, Sidyakina IV, Shapovalenko TV, Vasilyeva ES, Butenko AV, Shatveryan GA, Batukhtina EV, Kotenko KV. Koneva ES, et al. Among authors: mochalova as. Vopr Kurortol Fizioter Lech Fiz Kult. 2022;99(4. Vyp. 2):51-60. doi: 10.17116/kurort20229904251. Vopr Kurortol Fizioter Lech Fiz Kult. 2022. PMID: 36083818 Russian.
28 results